Related Experiment Video
Updated: Apr 21, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma
Hiroyuki Fujiwara1, Harushige Yokota, Bradley Monk
1*Jichi Medical University, Shimono-City, Japan and GOTIC; †Saitama Cancer Center, Saitama-City, Japan and GOTIC; ‡University of Arizona, Phoenix, AZ and GOG; §Centre Leon Berard, Lyon, France and GINECO; ∥Hospices Civils de Lyon, Lyon, France and GINECO; ¶The Canberra Hospital, Canberra, Australia and ANZGOG; #Seoul National University College of Medicine, Seoul, Korea and KGOG; **Universtatsklinikum Hamburg-Eppendorf, Hamburg, Germany and AGO; ††Walter Reed National Military Medical Center, Bethesda, MD and GOG; ‡‡Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Milan, Italy and MITO; and §§Saitama Medical University International Medical Center, Hidaka-City, Japan and GOTIC.
Abstract:
Cervical adenocarcinoma is known to be less common than squamous cell carcinoma of the cervix comprising approximately 25% of all cervical carcinomas. Differences in associated human papillomavirus types, patterns of spread, and prognosis call for treatments that are not always like those for squamous cancers. In this review, we report a consensus developed by the Gynecologic Cancer InterGroup surrounding cervical adenocarcinoma for epidemiology, pathology, treatment, and unanswered questions. Prospective clinical trials are needed to help develop treatment guidelines.
